The world's first!

The HPV market may usher in more strong competitors

Currently the world's highest HPV vaccine variety under development

Recently, the CDE official website shows that the clinical trial application of the recombinant 15-valent human papillomavirus vaccine (Escherichia coli) jointly developed by Chengda Biology and Recreation Guard has been approved for vaccination of women aged 9-45 to prevent HPV16, 18, Persistent infection of types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 and the resulting cervical, vulvar, vaginal and anal cancers; genital warts caused by HPV6 and 11 ; and the following lesions caused by HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68: Cervical intraepithelial neoplasia (CIN1/2/3 ), cervical adenocarcinoma in situ (AIS), vulvar intraepithelial neoplasia (VIN2/3), vaginal intraepithelial neoplasia (VaIN2/3), anal intraepithelial neoplasia (AIN1/2/3) and other related diseases

According to the official website of Chengda Biology, the 15-valent HPV vaccine developed in cooperation with Recreation Guard is currently the highest-valent HPV vaccine approved for clinical trials worldwide.

Domestic bivalent HPV vaccine sales boom

Relevant statistics show that cervical cancer has become the second largest malignant tumor in women.

The "price" in the HPV vaccine represents the types of viruses that the vaccine can prevent.

At present, the domestic HPV vaccine market is mainly divided into four types of vaccines, including Wantai Bio's Xinke Ning (bivalent), GlaxoSmithKline's Cervarix (bivalent), Merck's Gardasil (tetravalent) and Gardasil9 (9 price)

Among them, Wantai Bio's Xinkening is the first domestic and currently the only domestic HPV vaccine approved for marketing.

Due to the advantages of price and other factors, Xin Ke Ning ushered in a rapid increase in volume after its listing, surpassing Cervarix, which is also a bivalent product.

According to Wantai Bio's 2020 annual report performance, Xin Ke Ning achieved sales revenue of 693 million yuan in 2020.

Although Wantai Bio did not disclose the specific sales data of Xin Ke Ning in the 2021 performance bulletin, according to the centralized bidding and procurement of drugs by Wantai Bio, the total actual purchase volume of Xin Ke Ning in the medical structure in 2021 is 10.

Some analysts said that the sales of domestic bivalent HPV vaccines are hot.

It should be said that Wantai Bio’s bivalent HPV products have received market dividends, but this does not mean that it can sit back and relax.

Therefore, for Wantai Bio, there is no domestic alternative to the nine-valent HPV vaccine, which is a must for the next step

According to the relevant news of Wantai Bio, the company's nine-valent HPV vaccine has launched a phase III clinical trial

According to the statistics of Medical Valley, in addition to Wantai Bio, the domestic nine-valent HPV vaccine companies include Ruike Bio, Bowei Bio, and Kangle Guardian, and the products are all in the phase III clinical trial stage

In addition, there are higher-priced HPV vaccines under development, including China Pharmaceutical Group's 11-valent HPV vaccine and China Cell's 14-valent HPV vaccine